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Abstract
Objectives. Early remission is the current treatment strategy for patients with inflammatory polyarthritis
(IP) and RA. Our objective was to identify baseline factors associated with achieving remission: sustained
(SR), intermittent (IR) or never (NR) over a 5-year period in patients with early IP.
Methods. Clinical and demographic data of patients with IP recruited to the Norfolk Arthritis Register
(NOAR) were obtained at baseline and years 1, 2, 3 and 5. Remission was defined as no tender or swollen
joints (out of 51). Patients were classified as NR or PR, respectively, if they were in remission at: no
assessment or53 consecutive assessments after baseline, and IR otherwise. Ordinal regression and a
random effects model, respectively, were used to examine the association between baseline factors,
remission group and HAQ scores over time.
Results. A total of 868 patients (66% female) were included. Of these, 54%, 34% and 12% achieved NR,
IR and SR, respectively. In multivariate analysis, female sex (odds ratio, OR 0.47, 95% CI: 0.35, 0.63),
higher tender joint count (OR = 0.94, 95% CI: 0.93, 0.96), higher HAQ (OR = 0.59, 95% CI: 0.48, 0.74),
being obese (OR = 0.70, 95% CI: 0.50, 0.99), hypertensive (OR = 0.67, 95% CI: 0.50, 0.90) or depressed
(OR = 0.74, 95% CI: 0.55, 1.00) at baseline were independent predictors of being in a lower remission
group. IR and SR were associated with lower HAQ scores over time and lower DAS28 at year 5.
Conclusion. Women with higher tender joint count and disability at baseline, depression, obesity and
hypertension were less likely to achieve remission. This information could help when stratifying patients for
more aggressive therapy.
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Rheumatology key messages
. Factors including comorbidity and obesity are significant predictors of remission in inflammatory polyarthritis.
. Predictors of remission may be useful for stratifying patients with inflammatory polyarthritis for more aggressive
therapy.
. Patients with inflammatory polyarthritis who achieved remission had improved functional ability over a five-year
follow-up.
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Introduction
Remission, in patients with inflammatory polyarthritis (IP)
or its subset RA, can be defined as the absence of dis-
ease, with no detectable symptoms, signs or markers of
inflammation [1]. The ultimate aim of treatment for RA is to
achieve early and sustained remission [2]. In recent years,
remission has become a more realistic target due to im-
proved treatments and more aggressive regimes being
administered earlier in the disease course [3]. However,
in published studies remission rates vary considerably for
patients with IP, and it is difficult to identify at disease
onset which patients will ever achieve remission or
achieve sustained remission [4, 5].
Remission has the greatest beneficial impact on long-
term functional disability, work disability and radiographic
damage if it is sustained over a period of time [69].
In a systematic review including 18 papers published
prior to November 2008, Katchamart et al. [5] reported
that male sex, young age, late onset RA (age>65 years),
shorter disease duration, non-smoker, low baseline dis-
ease activity, lower functional impairment, absence
of RF and anti-CCP, early treatment with DMARD com-
binations and the concurrent use of DMARDs with TNF
inhibitors were predictors of remission at the end of
the study in patients with RA. However, most previous
studies of predictors of remission have assessed remis-
sion only at the end point of the study over a relatively
short follow-up period of between 1 and 3 years, and
often have not considered the impact of comorbidities
[1015].
The primary aim of this study was to identify fac-
tors measured at an early stage of disease that are asso-
ciated with sustained (SR), intermittent (IR) or never
achieving remission (NR) within the Norfolk Arthritis
Register (NOAR) over a 5-year follow-up. In addition,
we evaluated the association between remission
group and functional disability over time; and between
remission group and DAS28-CRP at the fifth year
anniversary.
Methods
Patients and setting
Patients recruited to NOAR, a primary-care-based incep-
tion cohort of patients with IP in Norfolk, UK, between
2000 and 2008 were included in this study [16]. The noti-
fication criteria were age over 16 years at symptom onset,
and swelling of at least two joints that has lasted for at
least 4 weeks. Patients were either referred by their gen-
eral practitioner or rheumatologist and were treated in
line with current national guidelines. Patients who were
later diagnosed with a condition other than IP, RA or
PsA, were excluded. We only included patients with
symptom duration of less than 2 years at baseline. This
study was given approval by the Norwich Local Research
Ethics Committee. All patients provided written informed
consent.
Demographic and clinical assessments
At baseline and at 1, 2, 3 and 5 years after baseline, pa-
tients were assessed by a research nurse. Information
collected included date of birth, sex, date of symptom
onset, smoking status (current, ex- or never), height and
weight (to compute BMI kg/m2), 51 swollen and tender
joint count, DMARD and other medication use. Patients
were classified as obese if they had a BMI5 30 kg/m2.
The British version of the HAQ was completed by the pa-
tient [17]. Self-reported physician-diagnosed comorbid-
ities were recorded by the research nurse, together with
year of diagnoses. Comorbidities were selected from a list
of predefined conditions [angina, hypertension, heart
attack, heart failure, stroke, transient ischaemic attack,
diabetes, stomach ulcer, liver disease, kidney failure,
cancer (except skin cancer), psoriasis, depression, glau-
coma] or recorded as free text. All comorbidity data
were coded according to the International Statistical
Classification of Diseases and Related Health Problems
10th Revision [18]. Blood samples were collected at base-
line and at the fifth year assessment and stored at 80C.
Subsequently, blood samples were tested for RF (by latex
method, positive at a titre of51:40), anti-CCP2 antibodies
(by Axis-Shield Diastat kit, positive at55 U/ml) and CRP
(by end point immunoturbidimetric agglutination method,
in milligram per litre). The three-component 28-joint
DAS28-CRP [19] was calculated at baseline and year 5.
The ACR/EULAR 2010 classification criteria for RA were
applied retrospectively using data collected at baseline
[20]. Patients who died during follow-up (n = 29) or who
had joint count data missing at one or more follow-up
visits (n = 267) were excluded from the analysis (see sup-
plementary Fig. S1, available at Rheumatology Online).
Definition of remission
Remission was defined as no tender or swollen joints on
examination of 51 joints. This definition provides a more
stringent definition of remission than using a count of
fewer joints and has previously been shown to be a
better predictor of functional disability and mortality [21].
These criteria were applied at the first, second, third and
fifth year assessments. Patients were classified as never
achieving remission (NR) if they were not in remission at
any anniversary, intermittently achieving remission (IR) if
they were in remission at least once but42 consecutive
assessments, and having sustained remission (SR) if they
were in remission at53 consecutive assessments.
Statistical analyses
The relationships between baseline variables and the
three remission groups were analysed using ordinal logis-
tic regression. Remission groups were ordered, with NR
being the lowest group and SR being the highest group.
The remission group was modelled as the dependent vari-
able in three separate models: univariate; including age,
sex and baseline oral steroid use as covariates; and
including covariates selected by a forward stepwise vari-
able selection procedure, with a significance value of<0.1
as the cut-off to be included in the model. All variables,
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apart from anti-CCP positivity (test for proportional odds,
P = 0.01), satisfied the proportional odds condition of or-
dinal regression. For anti-CCP, multinomial regression
analysis was used, and odds ratios for IR and SR are re-
ported separately, with NR as the referent group.
Separate ordinal regression analyses were performed:
with no data imputed and with missing values imputed
using Multiple Imputation by Chained Equations, with 20
imputations. The resulting models were compared. The
random number generator seed was set in the multiple
imputation process to ensure reproducible results. In the
models that included imputed values, time from symptom
onset to DMARD start date was replaced with the follow-
up duration (5 years) for patients who did not receive
DMARD treatment during follow-up. A dummy binary vari-
able indicating whether each patient had received
DMARD treatment during follow-up was considered in
combination with the time between symptom onset and
DMARD treatment in the stepwise variable selection pro-
cess; both the dummy variable and the time from symp-
tom onset to DMARD treatment had to reach the
significance value to be included in the stepwise model.
Separate sub-analysis of patients satisfying the 2010
ACR/EULAR criteria, and patients who were either RF-
positive or anti-CCPpositive at baseline were also carried
out.
To assess whether the pattern of HAQ scores over time
differed between remission groups, a random effects
model was used to allow for within-subject correlations.
Differences in median HAQ, mean DAS28-CRP and rela-
tive frequency of patients in each of the DAS28-CRP cate-
gories between the three remission groups were analysed
using a non-parametric test for trend (an extension of the
Wilcoxon rank-sum test). All analyses were conducted
using Stata V.13 (Stata Corp, College Station, TX, USA).
Results
A total of 868 patients with complete joint count data were
included in the primary analysis. Two-thirds (66%) were
female, and the median symptom duration at baseline was
6.5 [Interquartile Range (IQR): 4.111.1] months (Table 1).
Of these patients, 60% satisfied the 2010 ACR/EULAR
criteria for RA. Comparison between these 868 patients
and patients with missing joint count at51 follow-up visit
(293 patients, including 29 patients who died during fol-
low-up) showed statistically significant differences for, re-
spectively: proportion of females (66 vs 59%, P = 0.03),
number of swollen joints at baseline [median 3, IQR
(17) vs median 2, IQR (07), P = 0.02], proportion of pa-
tients satisfying the 2010 ACR/EULAR criteria for RA at
baseline (60 vs 47%, P< 0.001), proportion of patients
receiving DMARD treatment at baseline (51 vs 43%,
P = 0.009) and time between symptom onset and starting
DMARDs [median 6.28, IQR (3.9411.68) vs median 5.22,
IQR (3.0211.76) months, P = 0.04].
The numbers of patients in the NR, IR and SR groups
were 471 (54%), 296 (34%) and 101 (12%), respectively
(Table 1). In univariate ordinal regression analysis, female
sex was strongly associated with being in a lower
remission group (i.e. less likely to achieve remission)
(Table 2). Age at onset was not a predictor. A higher
number of swollen and tender joints, higher DAS28-
CRP, higher HAQ and satisfying 2010 ACR/EULAR criteria
for RA and having at least one comorbidity at baseline
were also significantly associated with being in a lower
remission group. Of the individual comorbidities con-
sidered, hypertension (odds ratio, OR = 0.67, 95% CI:
0.51, 0.87) and depression (OR = 0.52, 95% CI: 0.40,
0.69) were associated with being in a lower remission
group in univariate analysis. Obesity, although not con-
sidered as a comorbidity in the context of this study,
was also associated with reduced odds of being in a
higher remission category (OR = 0.49, 95% CI: 0.36,
0.66). These conditions were independently associated
with remission group when we added all three to a multi-
variate model adjusted for age and gender (data not
shown). Among patients who were receiving DMARD
treatment at baseline, the time from symptom onset to
starting DMARD treatment, modelled as a continuous
variable, was not significantly associated with remission
group in univariate ordinal regression analysis. However,
patients who started DMARD treatment within 3 months
of symptom onset (n = 117) were more likely to be in a
higher remission group (i.e. more likely to achieve remis-
sion) (OR = 1.66, 95% CI: 1.14, 2.42). These results re-
mained significant after adjusting for age, sex and steroid
use at baseline. Adjusting additionally for DMARD use at
baseline did not materially alter the results (data not
shown). Similar results were seen in sub-analyses of pa-
tients satisfying the 2010 ACR/EULAR criteria (Table 3),
and in patients who were RF- and/or anti-CCPpositive
(supplementary Table S1, available at Rheumatology
Online).
In multivariate regression analysis, female sex (OR =
0.47, 95% CI: 0.35, 0.63), higher tender joint count (OR
= 0.94, 95% CI: 0.93, 0.96), higher HAQ score (OR = 0.59,
95% CI: 0.48, 0.74), being obese (OR = 0.70, 95% CI:
0.50, 0.99), hypertensive (OR = 0.67, 95% CI: 0.50, 0.90)
or depressed (OR = 0.74, 95% CI: 0.55, 1.00) at baseline
were all independently associated with being in a lower
remission group (i.e. less likely to achieve remission)
(Table 2). Similar results were seen in a sub-analysis of
patients satisfying the 2010 ACR/EULAR criteria (Table 3).
HAQ scores differed significantly between remission
groups at baseline (Table 1) and over time (Table 4).
Using a random effects model to allow for within-person
correlation, we found that, after adjusting for age and sex,
IR and SR were associated with a lower HAQ score over
time compared with NR (b =0.51, 95% CI: 0.60, 0.43
for IR, b =0.85, 95% CI: 0.98, 0.72 for SR).
The mean (S.D.) DAS28-CRP score was significantly
higher at year 5 in the NR group [1.60 (0.94)] than in the
IR [0.54 (0.78)] or SR [0.23 (0.55)] groups (Table 4).
Similarly, a much higher proportion of patients in the SR
group were in DAS28-remission (83%) than in the IR
(61%) or NR (18%) group. The fact that 18% of the NR
group were in DAS28 remission at year 5 shows that our
remission criteria are stricter than the DAS28 criteria.
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TABLE 3 Baseline predictors of remission group for patients satisfying the 2010 ACR/EULAR criteria for RA at baseline
Characteristics
Model 1a Model 2b Model 3c
OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value
Age at onset, per year 1.00 (0.99, 1.01) 0.9   0.99 (0.97, 1.00) 0.09
Symptom duration, per month 1.00 (0.97, 1.04) 0.85 1.00 (0.96, 1.03) 0.88  
Female vs male 0.33 (0.22, 0.48) <0.001   0.36 (0.24, 0.54) <0.001
Swollen joints, per joint 0.97 (0.94, 1.00) 0.02 0.97 (0.94, 0.99) 0.02  
Tender joints, per joint 0.94 (0.92, 0.95) <0.001 0.94 (0.92, 0.95) <0.001 0.95 (0.93, 0.97) <0.001
CRP, per mg/l 1.00 (1.00, 1.01) 0.59 1.00 (1.00, 1.01) 0.49  
RF-positive, yes vs no 1.66 (1.13, 2.42) 0.009 1.56 (1.06, 2.31) 0.02  
Anti-CCPpositive, yes vs nod
Never remission Referent Referent Referent Referent  
Intermittent remission 2.12 (1.37, 3.28) 0.001 2.16 (1.38, 3.39) 0.001  
Sustained remission 1.26 (0.62, 2.54) 0.5 1.28 (0.62, 2.65) 0.5  
DAS28, per unit 0.58 (0.49, 0.70) <0.001 0.60 (0.50, 0.72) <0.001  
HAQ, per unit 0.41 (0.31, 0.54) <0.001 0.45 (0.34, 0.59) <0.001 0.63 (0.46, 0.84) 0.002
Time between symptom onset
and starting DMARDS,
per month)
0.99 (0.97, 1.01) 0.22 0.99 (0.97, 1.01) 0.28  
Starting DMARD treatment
within 3 months of
symptom onset,
yes vs no
1.59 (0.98, 2.58) 0.06 1.62 (0.99, 2.66) 0.06  
Never smoked Referent Referent Referent  
Current smoker 1.24 (0.77, 2.00) 0.38 0.92 (0.55, 1.54) 0.76  
Smoked in the past 1.27 (0.84, 1.90) 0.25 1.04 (0.67, 1.59) 0.87  
Obese, BMI >30 kg/m2,
yes vs no
0.52 (0.35, 0.79) 0.002 0.56 (0.37, 0.86) 0.009  
At least one comorbidity,e
yes vs no
0.78 (0.53,1.15) 0.21 0.0.77 (0.52, 1.15) 0.21  
Hypertensive 0.78 (0.54, 1.12) 0.18 0.72 (0.48, 1.06) 0.1  
Depressed 0.64 (0.45, 0.92) 0.02 0.70 (0.48, 1.02) 0.07  
aModel 1 is univariate analysis. bModel 2 is adjusted for age, sex and steroid use at baseline. cModel 3 includes covariates
selected by a stepwise procedure. A significance value of<0.1 was used as the cut-off to be included in the model.
dMultinomial regression analysis was used for anti-CCP, since this variable did not satisfy the proportional odds assumption
of ordinal regression. eAt least one of the following comorbidities: angina, hypertension, heart attack, heart failure, stroke,
transient ischaemic attack, diabetes, stomach ulcer, liver disease, kidney failure, cancer (except skin cancer), psoriasis,
depression, glaucoma.
TABLE 4 HAQ scores over time and DAS28 score at fifth year anniversary
Characteristics
Never remission Intermittent remission Sustained remission
Pa-value
n=471 n = 296 n = 101
HAQ, median (IQR)
First anniversary 1 (0.51.75) 467 0.5 (01) 293 0.125 (00.38) 101 <0.001
Second anniversary 1.25 (0.631.75) 467 0.375 (0.131) 293 0 (00.25) 100 <0.001
Third anniversary 1.125 (0.631.88) 469 0.38 (01) 294 0 (00.25) 100 <0.001
Fifth anniversary 1.25 (0.631.88) 469 0.38 (01) 287 0 (00.25) 100 <0.001
DAS28-CRP, mean (S.D.)
Fifth anniversary 1.60 (0.94) 232 0.54 (0.78) 134 0.23 (0.55) 52 <0.001
DAS28-CRP category, fifth anniversary, %
Remission, DAS28 <2.6 17.7 41/232 61.2 82/134 82.7 43/52 <0.001
Low disease activity,
2.64DAS28<3.2
19.4 45/232 25.4 34/134 11.5 6/52
Moderate disease activity,
3.24DAS28<5.1
48.3 112/232 11.2 15/134 5.8 3/52
High disease activity, DAS2855.1 14.7 34/232 2.2 3/134 0.0 0/52
aP-value from non-parametric test for trend.
6 www.rheumatology.oxfordjournals.org
Michael J. Cook et al.
 at U
niversity of East A
nglia on M
ay 31, 2016
http://rheum
atology.oxfordjournals.org/
D
ow
nloaded from
 
Discussion
In this observational study of patients with IP, we found
that 46% of patients were in remission [defined as no
swollen or tender joints (out of 51)] at one or more time-
points during a 5-year follow-up period. Thirty-four per-
cent of patients achieved IR and only 12% of patients
achieved SR in that time frame. Female sex, higher
tender joint counts, higher HAQ score and being hyper-
tensive, depressed or obese at baseline were independ-
ent predictors of being in a lower remission group (i.e. of
being less likely to achieve remission). Starting DMARD
treatment within 3 months of symptom onset was asso-
ciated with being in a higher remission group (i.e. being
more likely to achieve remission), but only in univariate
and age, sex and steroid use at baseline adjusted
analyses.
Comparison of remission rates between studies is diffi-
cult because of differences in definitions of remission, the
number of times remission was assessed, stage of dis-
ease, patient characteristics and treatment regimens be-
tween studies. The systematic review conducted
Katchamart et al. [5] included papers reporting remission
rates varying from 4 to 53%. Remission criteria proposed
for RA include some based on thresholds of disease ac-
tivity measures such as the DAS28 [22], the Simplified
Disease Activity Index [23] or the Clinical Disease
Activity Index [24]; some based on a long list of symptoms
such as the strict preliminary criteria proposed by Pinals
et al. [25] or Boolean logic such as the 2011 ACR/EULAR
definition [26]. The choice of remission definition has a
marked effect on the proportion of patients classified as
being in remission [2730]. For example, Kuriya et al. [29]
found that the ACR/EULAR Boolean criteria and the
DAS28 criteria for remission classified 18 and 40%, re-
spectively, of patients with early RA as being in remission
at 12 months follow-up.
In our cohort, 46% of patients achieved at least IR + SR
during a 5-year follow-up. Only 12% of patients achieved
persistent remission. Ellerby et al. [31] reported 44/295
(14.9%) patients achieved SR, defined as DAS28< 2.6
at two consecutive time points, measured annually over
a 5-year follow-up. Gossec et al. [32] reported 30/191
(15.7%) achieved SR, defined as DAS< 1.6 [32] at both
third and fifth year anniversaries. In our cohort, only 5% of
women achieved persistent remission, compared with
19% of men, which is in agreement with other studies
reporting that women are less likely to achieve remission
[13, 15, 33, 34]. The reasons why women are less likely to
achieve remission are unclear, although sex hormones
may play a role in the pathophysiology of RA, with andro-
gens anti-inflammatory and oestrogens immune response
enhancers at physiological concentrations [34]. It is also
possible that women may be more likely to have co-ex-
istent primary general OA, contributing to a higher tender
joint count.
Patients who were obese at baseline were less likely to
achieve remission, independent of other comorbidities.
Other studies have reported a similar negative association
between obesity and remission and low disease activity
[31, 35, 36]. With the prevalence of obesity rising globally
[37], this is likely to become an increasingly important
factor in determining outcome for patients. Adipose
tissue functions as an endocrine organ, releasing pro-in-
flammatory and anti-inflammatory adipokines, which
could play a role in sustaining joint inflammation and
raised inflammatory markers [38, 39].
We found that patients in the IR and NR group were
more likely to be depressed at baseline. There is prior
evidence of a relationship between inflammation and de-
pression [40, 41], with a suggestion that depression may
precede inflammation [42, 43]. While we cannot be sure
that depressive symptoms preceded disease symptoms
at baseline in our cohort, it is possible that pre-existing
depressive symptoms may influence disease progression.
There is a bi-directional relationship between functional
disability and depression in patients with chronic medical
illness [44]. Functional disability predicts the development
of depression, and depressive symptoms are a risk factor
for the progression of disability. Additionally, depression
has been linked to adverse health-risk behaviour such as
smoking, overeating and non-compliance with recom-
mended treatment.
Strengths of our study include a large cohort of patients
with early IP, with detailed clinical, treatment, demo-
graphic and comorbidity data. Having a 5-year follow-up
allowed us to identify baseline factors associated with IR
and SR, rather than factors associated with remission at a
single point in time. Limitations of our study include our
definition of remission, which does not include a blood
marker of inflammation. We were not able to include a
blood marker of inflammation in our definition of remission
because blood was collected only at the baseline and fifth
year assessments. This could result in some misclassifi-
cation of patients who are in remission of their inflamma-
tory arthritis but have one or more tender joints due to
other conditions such as FM. However, the definition of
remission we have used is strict and, unlike the DAS-28
definition of remission, does not allow for any swollen or
tender joints [45]. Our findings that women and patients
with a higher HAQ score at baseline were less likely to
achieve remission is in agreement with other studies
using a DAS28 definition of remission [46, 47]. It is
known that patients with RA can have altered body com-
position, with a decrease in lean muscle mass. Other
methods of determining obesity, such as hip to waist
ratio, bioimpedence, or whole-body MRI may be more
appropriate for patients with RA [48], though these meas-
urements were not taken in our study. Another limitation of
our study is that comorbidities were self-reported.
Conclusions
The current aim of the treatment of IP and RA is to achieve
early and sustained remission. However, in our study we
found that only about 12% of patients with IP achieved
sustained remission (by our definition) during a 5-year
follow-up. Sex, number of tender joints, HAQ score and
being obese, hypertensive or depressed at baseline were
all independently associated with the remission group.
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These factors may be useful in predicting which patients
are likely to achieve remission and, thus, in guiding treat-
ment choice and timing.
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